Barrier Therapeutics, Inc. Introduces Dual-Component Xolegel CorePak(TM) for Seborrheic Dermatitis

Published: Jul 28, 2008

PRINCETON, NJ--(Marketwire - July 28, 2008) - Barrier Therapeutics, Inc. (NASDAQ: BTRX) announced today the introduction of Xolegel CorePakā„¢ for the treatment of seborrheic dermatitis. Now, patients with this chronic skin condition need only one prescription to get quick itch relief and to safely manage the overall condition long term.

Back to news